Sei Investments Co. Purchases 18,655 Shares of West Pharmaceutical Services Inc. (NYSE:WST)

Share on StockTwits

Sei Investments Co. grew its holdings in shares of West Pharmaceutical Services Inc. (NYSE:WST) by 51.4% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 54,983 shares of the medical instruments supplier’s stock after acquiring an additional 18,655 shares during the quarter. Sei Investments Co. owned 0.07% of West Pharmaceutical Services worth $4,854,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of WST. Alliancebernstein L.P. raised its stake in West Pharmaceutical Services by 75.8% during the fourth quarter. Alliancebernstein L.P. now owns 2,042,166 shares of the medical instruments supplier’s stock worth $201,500,000 after acquiring an additional 880,636 shares in the last quarter. USS Investment Management Ltd acquired a new position in shares of West Pharmaceutical Services in the first quarter valued at approximately $76,978,000. WCM Investment Management CA acquired a new position in shares of West Pharmaceutical Services in the first quarter valued at approximately $50,148,000. TCW Group Inc. increased its stake in shares of West Pharmaceutical Services by 127.0% in the fourth quarter. TCW Group Inc. now owns 715,727 shares of the medical instruments supplier’s stock valued at $70,621,000 after buying an additional 400,459 shares during the period. Finally, Carillon Tower Advisers Inc. acquired a new position in shares of West Pharmaceutical Services in the fourth quarter valued at approximately $39,036,000. 94.45% of the stock is owned by hedge funds and other institutional investors.

In other West Pharmaceutical Services news, CFO William J. Federici sold 42,869 shares of the firm’s stock in a transaction on Friday, June 8th. The stock was sold at an average price of $96.09, for a total transaction of $4,119,282.21. Following the transaction, the chief financial officer now directly owns 270,681 shares in the company, valued at approximately $26,009,737.29. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO William J. Federici sold 52,000 shares of the firm’s stock in a transaction on Wednesday, May 9th. The shares were sold at an average price of $87.14, for a total value of $4,531,280.00. Following the sale, the chief financial officer now directly owns 247,019 shares of the company’s stock, valued at $21,525,235.66. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 99,869 shares of company stock worth $9,136,762. Company insiders own 1.90% of the company’s stock.

Several research analysts have recently issued reports on the company. ValuEngine raised West Pharmaceutical Services from a “sell” rating to a “hold” rating in a research note on Tuesday, June 12th. Zacks Investment Research raised shares of West Pharmaceutical Services from a “sell” rating to a “hold” rating in a research report on Saturday, June 2nd. Finally, Bank of America downgraded shares of West Pharmaceutical Services from a “neutral” rating to an “underperform” rating and set a $85.00 target price for the company. in a research report on Wednesday, April 25th. Two equities research analysts have rated the stock with a sell rating, four have assigned a hold rating and two have assigned a buy rating to the company. The stock has a consensus rating of “Hold” and an average target price of $106.00.

Shares of West Pharmaceutical Services stock traded up $0.07 on Friday, reaching $100.99. 1,025,224 shares of the company’s stock were exchanged, compared to its average volume of 316,836. West Pharmaceutical Services Inc. has a 52 week low of $80.02 and a 52 week high of $103.36. The company has a debt-to-equity ratio of 0.15, a quick ratio of 2.00 and a current ratio of 2.82. The stock has a market capitalization of $7.43 billion, a price-to-earnings ratio of 36.33, a PEG ratio of 3.27 and a beta of 1.11.

West Pharmaceutical Services (NYSE:WST) last issued its earnings results on Thursday, April 26th. The medical instruments supplier reported $0.62 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.64 by ($0.02). West Pharmaceutical Services had a return on equity of 14.40% and a net margin of 8.20%. The firm had revenue of $415.70 million during the quarter, compared to the consensus estimate of $403.87 million. During the same quarter in the prior year, the business earned $0.60 earnings per share. West Pharmaceutical Services’s revenue for the quarter was up 7.2% on a year-over-year basis. equities research analysts forecast that West Pharmaceutical Services Inc. will post 2.81 EPS for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, August 1st. Shareholders of record on Wednesday, July 18th will be paid a dividend of $0.14 per share. This represents a $0.56 annualized dividend and a yield of 0.55%. The ex-dividend date is Tuesday, July 17th. West Pharmaceutical Services’s dividend payout ratio (DPR) is presently 20.14%.

West Pharmaceutical Services Profile

West Pharmaceutical Services, Inc manufactures and sells containment and delivery systems for injectable drugs and healthcare products in the United States, Germany, France, Other European countries, and internationally. The company operates through two segments, Proprietary Products and Contract-Manufactured Products.

Institutional Ownership by Quarter for West Pharmaceutical Services (NYSE:WST)

Receive News & Ratings for West Pharmaceutical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply